A Phase I/IIa Dose Escalation Study of Repeated Administration of CYT107 (glyco-r-hIL-7) Add On Treatment in Genotype 1 or 4 HCV Infected Patients Resistant To Pegylated Interferon-Alpha and Ribavirin.

Trial Profile

A Phase I/IIa Dose Escalation Study of Repeated Administration of CYT107 (glyco-r-hIL-7) Add On Treatment in Genotype 1 or 4 HCV Infected Patients Resistant To Pegylated Interferon-Alpha and Ribavirin.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2012

At a glance

  • Drugs Interleukin-7; Peginterferon alfa; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Acronyms ECLIPSE-2
  • Sponsors Revimmune SAS
  • Most Recent Events

    • 17 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 17 Oct 2012 Planned end date changed from 1 Jun 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov record.
    • 24 Mar 2012 Planned number of patients changed from 18 to 36 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top